Menu Search
Equities

Abeona Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
PCJ:FRA

Abeona Therapeutics Inc

Actions
  • Price (EUR)4.06
  • Today's Change-0.14 / -3.33%
  • Shares traded20.00
  • 1 Year change-26.85%
  • Beta1.1280
Data delayed at least 15 minutes, as of Feb 06 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).

  • Revenue in USD (TTM)400.00k
  • Net income in USD82.35m
  • Incorporated1989
  • Employees136.00
  • Location
    Abeona Therapeutics Inc6555 CARNEGIE AVE, 4TH FLOORCLEVELAND 44103United StatesUSA
  • Phone+1 (646) 813-4701
  • Fax+1 (302) 655-5049
  • Websitehttps://abeonatherapeutics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.